If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Carrigen(R) Porous Bone Substitute Material - The First Hard Setting, Highly Porous Bone Graft Substitute CAMBRIDGE, Mass., March 9 (HSMN NewsFeed) –ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) c…
Devices, Orthopaedic, FDA
ETEX Corp, CarriGen, Bone Substitute
Posts on ‘March 9th, 2010’
ETEX Corporation Announces FDA Clearance and Launch of Carrigen(R) Porous Bone Substitute Material
Positron Corporation Cites JACR Study That Reports a 737% Growth Rate in PET among 5 Speciality Groups Including Cardiology
INDIANAPOLIS–(HSMN NewsFeed)–Positron Corporation (OTCBB:POSC ). The growth rate among nonradiologists who own or lease PET equipment was far higher than radiologists between 2002 and 2007, according to a study published in the March issue of the Journal…
Devices, Radiology, Oncology, Cardiology
Positron Corp, positron emission tomography, PET imaging
Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application
VANCOUVER, British Columbia–(HSMN NewsFeed)–Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has received from the Food and Drug Administration (FDA) an Investigational Device Exemption (IDE) approval to initiate a pivotal Phase …
Devices, Oncology, FDA
Medifocus, Microfocus, hyperthermia therapy, breast cancer
Orthopaedic Synergy, Inc. Announces Letter of Intent to Acquire Praxim, SA
EAST TAUNTON, Mass., March 9 (HSMN NewsFeed) — Orthopaedic Synergy, Inc., is pleased to announce that it has entered into a letter of intent and period of exclusivity to acquire Praxim, SA of France. "The acquisition of Praxim SA will represe…
Devices, Orthopaedic, Mergers & Acquisitions
Orthopaedic Synergy, Praxim
